<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05625503</url>
  </required_header>
  <id_info>
    <org_study_id>2022-0722</org_study_id>
    <nct_id>NCT05625503</nct_id>
  </id_info>
  <brief_title>Dilution of Verapamil During Intraarterial Administration</brief_title>
  <official_title>Does Dilution of Verapamil With Normal Saline or Blood Reduce Discomfort Felt During Intraarterial Administration?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a randomized, single-blind, prospective trial designed to evaluate the&#xD;
      efficacy and safety of intra-arterial (IA) Verapamil diluted with normal saline compared to&#xD;
      undiluted IA Nicardipine during transradial access (TRA) for percutaneous coronary&#xD;
      angiography. Patients who are 18 years or older and undergoing non-emergent percutaneous&#xD;
      coronary angiography via TRA will be included. Patients who are non-English speaking,&#xD;
      pregnant, or intubated will be excluded. Patients will be randomized to one of the two&#xD;
      following groups:&#xD;
&#xD;
        1. Group 1 will receive IA Verapamil 5 mg (2mL) diluted with 8 mL of normal saline&#xD;
&#xD;
        2. Group 2 will receive IA Nicardipine 400 mcg (undiluted, 8 mL)&#xD;
&#xD;
      The investigators will document the patient's level of discomfort on the Visual Analogue&#xD;
      Scale 30 seconds before and after administration of IA Verapamil/Nicardipine. The&#xD;
      investigators will also document the presence of radial artery spasms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 14, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radial Artery Spasm</measure>
    <time_frame>approximately 30 minutes</time_frame>
    <description>The investigators will document the presence or absence of radial artery spasms with either 0,1, or 2. 0 will indicate no radial artery spasms. 1 will indicate radial artery spasms that did not require a change in strategy. 2 will indicate radial artery spasms that required a change in strategy such as alternate access.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Prior to Intra-arterial Calcium Channel Blocker Administration</measure>
    <time_frame>30 seconds prior to administration</time_frame>
    <description>Pain prior to intra-arterial calcium channel blocker administration will be assessed through the Visual Analogue Pain scale (from 0 to 10).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain After Intra-arterial Calcium Channel Blocker Administration</measure>
    <time_frame>30 seconds post administration</time_frame>
    <description>Pain after intra-arterial calcium channel blocker administration will be assessed through the Visual analogue Pain Scale (from 0 to 10).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vasospasm;Peripheral</condition>
  <condition>Burning</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-arterial Verapamil 5 mg (2mL) diluted with 8 mL of normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicardipine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intra-arterial Nicardipine 400 mcg undiluted (8mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>All patients routinely receive intra-arterial calcium channel blockers during transradial access for coronary angiography.</description>
    <arm_group_label>Verapamil</arm_group_label>
    <other_name>Calcium channel blocker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine</intervention_name>
    <description>Calcium channel blocker</description>
    <arm_group_label>Nicardipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  English Speaking patients who are age 18 or older&#xD;
&#xD;
          -  Patient must be able to provide own consent and communicate with staff&#xD;
&#xD;
          -  Patient's undergoing transradial access (TRA) for the left heart catheterization (LHC)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Intubated or sedated patients&#xD;
&#xD;
          -  Agitated patients requiring moderate sedation prior to TRA&#xD;
&#xD;
          -  Patient's undergoing femoral access for the LHC&#xD;
&#xD;
          -  Non-English speaking patients&#xD;
&#xD;
          -  Contraindications to Verapamil or Nicardipine: including allergies to these&#xD;
             medications, hypotension (mean arterial pressure &lt;65), Bradycardia (heart rate&lt;40)&#xD;
&#xD;
          -  Emergent cardiac catheterization&#xD;
&#xD;
          -  Inability to obtain radial artery access&#xD;
&#xD;
          -  Conversion to radial artery access from another access site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khalil Ibrahim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keshav R Patel, MD MS</last_name>
    <phone>734-306-3130</phone>
    <email>kpate447@uic.edu</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 11, 2022</study_first_submitted>
  <study_first_submitted_qc>November 21, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>November 21, 2022</last_update_submitted>
  <last_update_submitted_qc>November 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Khalil Ibrahim</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>cardiac catheterization</keyword>
  <keyword>intra-arterial calcium channel blockers</keyword>
  <keyword>radial artery spasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Nicardipine</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

